Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
IEEE

Influence-Balanced XGBoost: Improving XGBoost for Imbalanced Data Using Influence Functions

Abstract: Decision tree boosting algorithms, such as XGBoost, have demonstrated superior predictive performance on tabular data for supervised learning compared to neural networks. However, recent ...

Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform

Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.